)
Visual
test
Atara Biotherapeutics
Atara Biotherapeutics (ATRA) investor relations material
Atara Biotherapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Tab-cel received marketing authorization in Europe, UK, and Switzerland, with U.S. Phase 3 development ongoing and BLA accepted by FDA for Priority Review, target action date January 10, 2026.
All tab-cel activities and costs have been transferred to Pierre Fabre, expanding their global commercialization rights.
Multiple workforce reductions in 2025, reducing headcount to approximately 15 by October and implementing a 29% reduction.
Allogeneic CAR T cell programs and other pipeline assets were paused or discontinued, with rights to certain programs returned to partners.
Strategic alternatives, including M&A or asset sales, are under review to maximize shareholder value, with no assurance of outcome.
Financial highlights
Net income of $36.1 million for the nine months ended September 30, 2025, compared to a net loss of $72.7 million in the prior year period.
Q3 2025 net loss was $4.3 million ($0.32 per share), compared to $21.9 million ($2.93 per share) in Q3 2024.
Commercialization revenue was $119.2 million for the nine months ended September 30, 2025, up from $96.2 million year-over-year.
Cash, cash equivalents, and short-term investments totaled $13.7 million as of September 30, 2025, down from $42.5 million at year-end 2024.
Research and development expenses dropped to $2.9 million in Q3 2025 from $43.9 million in Q3 2024.
Outlook and guidance
Eligible for a $40 million milestone payment upon FDA approval of tab-cel BLA, plus double-digit tiered royalties and additional milestones.
Cash and investments, plus the anticipated milestone, are expected to provide significant runway, but current resources are insufficient to fund operations for 12 months beyond the report date.
Additional capital will be required in the near term, with plans to seek funding through equity, debt, or strategic transactions.
Full-year 2025 operating expenses expected to decrease by at least 60% versus 2024 due to cost transitions and operational efficiencies.
Beyond tab-cel, what are Atara's core activities?
What is the scope of strategic alternatives?
Projected cash runway after tab-cel milestone?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
Next Atara Biotherapeutics earnings date
Q4 202513 Mar, 2026
Atara Biotherapeutics
Next Atara Biotherapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Atara Biotherapeutics Inc. is a biotechnology company focused on developing therapies for cancer, autoimmune, and viral diseases. The company specializes in allogeneic T-cell immunotherapy, using off-the-shelf T-cells to target and treat diseases. Atara's lead programs are centered around developing treatments for conditions such as Epstein-Barr virus-associated cancers and multiple sclerosis. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage